# Outlook Therapeutics, Inc.: Form 8-K, filed May 13, 2026

- Company: [Outlook Therapeutics, Inc.](/companies/otlk.md) (CIK 1649989)
- Form: 8-K
- Filed: 2026-05-13
- Accepted by EDGAR: May 13, 2026, 20:36 ET
- Period: 2026-05-12
- Accession: 0001104659-26-060305
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1649989/000110465926060305/tm2614480d1_8k.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1649989/000110465926060305/

## Items reported

- Item 1.01: Entry into a material agreement
- Item 1.02: Termination of a material agreement
- Item 2.02: Results of operations
- Item 9.01: Financial statements and exhibits

## Sections

Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. https://www.sec.gov/Archives/edgar/data/1649989/000110465926060305/tm2614480d1_8k.htm

Filed May 13, 2026.
Source: SEC EDGAR, the filing index for accession 0001104659-26-060305. Last ingested by Listed: Oct 24, 2026, 15:14 ET. No prices; not investment advice.
